OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MBX Biosciences
MBX
|
+$87.2M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
+$46.7M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$42.6M |
| 4 |
Amgen
AMGN
|
+$38.4M |
| 5 |
UnitedHealth
UNH
|
+$37.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Janux Therapeutics
JANX
|
+$74.9M |
| 2 |
Tenet Healthcare
THC
|
+$59.2M |
| 3 |
VRNA
Verona Pharma
VRNA
|
+$41.4M |
| 4 |
Geron
GERN
|
+$40.6M |
| 5 |
Vaxcyte
PCVX
|
+$36.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.88% |
| 2 | Miscellaneous | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.22B
| $401M | 7.29% |
15,021,721
| – | – |
2021 Q1
14 quarters
|
|
|
SVA
2
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.18% |
2,718,735
| – | – |
2022 Q2
9 quarters
|
|
3
Eli Lilly
LLY
$1.26T
| $299M | 5.43% |
337,600
| – | – |
2023 Q1
6 quarters
|
|
4
Boston Scientific
BSX
$60.8B
| $274M | 4.98% |
3,273,000
| – | – |
2014 Q1
42 quarters
|
|
5
Intuitive Surgical
ISRG
$153B
| $213M | 3.87% |
433,800
-59,300
| -12% | -$27.6M |
2013 Q4
43 quarters
|
|
6
Enliven Therapeutics
ELVN
$3.24B
| $203M | 3.69% |
7,959,538
| – | – |
2020 Q1
18 quarters
|
|
7
Biogen
BIIB
$37.5B
| $158M | 2.86% |
813,000
-87,900
| -10% | -$18.4M |
2013 Q2
45 quarters
|
|
8
Merck
MRK
$369B
| $149M | 2.72% |
1,316,000
| – | – |
2023 Q3
4 quarters
|
|
|
9
Tenet Healthcare
THC
$22B
| $130M | 2.36% |
782,000
-391,300
| -33% | -$59.2M |
2021 Q3
12 quarters
|
|
10
Stryker
SYK
$112B
| $124M | 2.26% |
344,400
+75,400
| +28% | +$26M |
2020 Q3
16 quarters
|
|
11
ARS Pharmaceuticals
SPRY
$336M
| $120M | 2.18% |
8,288,510
-952,377
| -10% | -$11.3M |
2020 Q4
15 quarters
|
|
|
12
Sarepta Therapeutics
SRPT
$1.97B
| $119M | 2.17% |
954,500
+308,500
| +48% | +$42.6M |
2017 Q4
27 quarters
|
|
13
argenx
ARGX
$56.1B
| $111M | 2.01% |
204,500
-4,600
| -2% | -$2.32M |
2022 Q1
10 quarters
|
|
|
14
UnitedHealth
UNH
$365B
| $105M | 1.9% |
179,000
+67,000
| +60% | +$37.9M |
2020 Q4
15 quarters
|
|
15
Q32 Bio
QTTB
$265M
| $101M | 1.83% |
2,252,987
| – | – |
2024 Q1
2 quarters
|
|
|
16
MBX Biosciences
MBX
$2.69B
| $99M | 1.8% |
+3,812,215
| New | +$87.2M |
2024 Q3
0 quarters
|
|
17
Ionis Pharmaceuticals
IONS
$7.23B
| $93.1M | 1.69% |
2,324,447
-47,886
| -2% | -$2.23M |
2022 Q2
9 quarters
|
|
18
Disc Medicine
IRON
$3.59B
| $87.7M | 1.59% |
1,785,571
| – | – |
2021 Q1
14 quarters
|
|
19
Natera
NTRA
$59.7B
| $87.3M | 1.59% |
687,500
| – | – |
2015 Q3
36 quarters
|
|
|
20
Amgen
AMGN
$252B
| $81.3M | 1.48% |
252,300
+117,400
| +87% | +$38.4M |
2023 Q1
6 quarters
|
|
21
DELISTED
Third Harmonic Bio
THRD
| $78.3M | 1.42% |
5,779,071
| – | – |
2022 Q3
8 quarters
|
|
22
Integer Holdings
ITGR
$4.3B
| $74.8M | 1.36% |
575,000
+225,779
| +65% | +$27.6M |
2024 Q2
1 quarter
|
|
23
ArriVent BioPharma
AVBP
$733M
| $71.1M | 1.29% |
3,027,328
| – | – |
2024 Q1
2 quarters
|
|
24
Vertex Pharmaceuticals
VRTX
$142B
| $70.2M | 1.28% |
151,000
| – | – |
2013 Q2
45 quarters
|
|
25
Alnylam Pharmaceuticals
ALNY
$22.1B
| $68.8M | 1.25% |
250,300
| – | – |
2024 Q2
1 quarter
|
|
Similar funds
OrbiMed's Q3 2024 Portfolio in Review
As of Q3 2024, OrbiMed held 136 positions worth $5.5B, up 8.7% from $5.06B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
OrbiMed's Q3 2024 filing shows 22 new, 21 increased, 31 reduced and 18 closed positions. Its largest new stake was MBX Biosciences: 3,812,215 shares worth $99M. The largest sale was Janux Therapeutics, an estimated $74.9M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.
- OrbiMed's largest Q3 2024 buy was MBX Biosciences: 3,812,215 shares worth $99M.
- OrbiMed added most to Sarepta Therapeutics in Q3 2024, an estimated $42.6M increase.
- OrbiMed's biggest Q3 2024 reduction was Janux Therapeutics, cutting an estimated $74.9M.
- OrbiMed fully exited Verona Pharma in Q3 2024, selling an estimated $41.4M.
- OrbiMed's ten largest holdings make up 42% of its $5.5B portfolio in Q3 2024.
- OrbiMed opened 22 new positions and closed 18 in Q3 2024.
- OrbiMed's portfolio value rose 8.7% quarter-over-quarter to $5.5B.
Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.